Vaxart, Inc.

Equities

VXRT

US92243A2006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:08:10 2024-03-28 pm EDT 5-day change 1st Jan Change
1.355 USD +5.04% Intraday chart for Vaxart, Inc. +10.16% +136.56%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall MT
Vaxart, Inc. Announces Chief Executive Officer Changes CI
Vaxart, Inc. Announces Management Appointments CI
North American Morning Briefing : Stock Futures -2- DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50 MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study MT
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise MT
Vaxart, Inc. Announces CEO Changes CI
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director CI
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers CI
Transcript : Vaxart, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (VXRT) VAXART Posts Q3 Revenue $2.1M MT
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers CI
Vaxart Says Topline Data From Phase 2 Challenge Study of Monovalent Norovirus Vaccine Meets 5 of 6 Endpoints MT
Transcript : Vaxart, Inc. - Special Call
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate CI
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating MT
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Vaxart, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (VXRT) VAXART Reports Q2 Revenue $1.4M, vs. Street Est of $0.08M MT
Certain Warrants of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023. CI
Certain Restricted Stock Units of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023. CI
Chart Vaxart, Inc.
More charts
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.29 USD
Average target price
5 USD
Spread / Average Target
+287.60%
Consensus
  1. Stock
  2. Equities
  3. Stock Vaxart, Inc. - Nasdaq
  4. News Vaxart, Inc.
  5. Vaxart : Earnings Flash (VXRT) VAXART Reports Q4 Revenue $356,000